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ABSTRACT	
	
To	examine	for	a	causal	relationship	between	vitamin	D	and	glioma	risk	we	performed	an	
analysis	of	genetic	variants	associated	with	serum	25-hydroxyvitamin	D	(25(OH)D)	levels	
using	Mendelian	randomisation	(MR),	an	approach	unaffected	by	biases	from	confounding.	
Two-sample	MR	was	undertaken	using	genome-wide	association	study	data.	Single	
nucleotide	polymorphisms	(SNPs)	associated	with	25(OH)D	levels	were	used	as	instrumental	
variables	(IVs).	We	calculated	MR	estimates	for	the	odds	ratio	(OR)	for	25(OH)D	levels	with	
glioma	using	SNP-glioma	estimates	from	12,488	cases	and	18,169	controls,	using	inverse-
variance	weighted	(IVW)	and	maximum	likelihood	estimation	(MLE)	methods.	A	non-
significant	association	between	25(OH)D	levels	and	glioma	risk	was	shown	using	both	the	
IVW	(OR=1.21,	95%	confidence	interval	[CI]=0.90-1.62,	P=0.201)	and	MLE	(OR=1.20,	95%	
CI=0.98-1.48,	P=0.083)	methods.	In	an	exploratory	analysis	of	tumour	subtype,	an	inverse	
relationship	between	25(OH)D	levels	and	glioblastoma	(GBM)	risk	was	identified	using	the	
MLE	method	(OR=0.62,	95%	CI=0.43-0.89,	P=0.010),	but	not	the	IVW	method	(OR=0.62,	95%	
CI=0.37-1.04,	P=0.070).	No	statistically	significant	association	was	shown	between	25(OH)D	
levels	and	non-GBM	glioma.	Our	results	do	not	provide	evidence	for	a	causal	relationship	
between	25(OH)D	levels	and	all	forms	of	glioma	risk.	More	evidence	is	required	to	explore	
the	relationship	between	25(OH)D	levels	and	risk	of	GBM.			
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INTRODUCTION	
	
While	glioma	accounts	for	around	80%	of	malignant	primary	brain	tumours	1,	thus	far	
exposure	to	ionising	radiation	is	the	only	well-established	exogenous	risk	factor	2.	Vitamin	D	
provides	many	health	benefits,	including	increased	bone	strength	and	protection	against	
autoimmune	diseases	and	type	2	diabetes	3.	In-vitro	studies	have	also	suggested	an	anti-
neoplastic	role	for	vitamin	D	4.	Several	epidemiological	studies	have	shown	that	vitamin	D	
may	indeed	afford	protection	against	the	development	of	some	cancers,	including	colon,	
prostate	and	breast	cancer	5.	Associations	in	such	observational	studies	do	not	however	
constitute	evidence	for	a	causal	relationship	and	in	some	studies	bias	from	confounding	and	
reverse	causation	cannot	be	excluded.		
	
Mendelian	randomisation	(MR)	uses	genetic	markers	as	proxies	for	environmental	
exposures	to	determine	the	effect	of	the	exposure	on	disease	risk	6.	It	therefore	provides	a	
strategy	for	establishing	causal	relationships	where	randomised	control	trials	(RCTs)	would	
involve	either	high	cost	or	impractical	study	design.	In	the	case	of	a	possible	relationship	
between	vitamin	D	and	glioma,	the	rarity	of	the	cancer	would	limit	any	RCT	to	small	sample	
sizes	and	would	require	lengthy	follow	up	times.		
	
We	implemented	two-sample	MR	analysis	to	examine	the	relationship	between	vitamin	D	
and	glioma	risk	in	order	to	avoid	the	limitations	of	follow	up	time,	reverse	causation	and	
confounding.	Genotypes	are	randomly	assigned	at	conception,	thereby	limiting	
confounding.	Furthermore	an	individual’s	genotype	will	always	be	established	before	the	
onset	of	disease,	excluding	the	possibility	of	reverse	causation.	The	genotype	is	in	part	
equivalent	to	a	lifetime	vitamin	D	deficiency,	and	hence	a	lifetime	follow-up	time	in	a	RCT.	
We	determine	the	relationship	between	vitamin	D	and	glioma	risk	using	genetic	variants	
associated	with	25(OH)D	levels,	rather	than	measuring	25(OH)D	levels	directly.		
	
Genetic	variants	identified	by	the	Study	of	Underlying	Genetic	Determinants	of	Vitamin	D	
and	Highly	Related	Traits	(SUNLIGHT)	Consortium	7	and	the	Canadian	Multicentre	
Osteoporosis	Study	(CaMOS)	8	were	used	as	an	instrumental	variable	(IV).	We	performed	an	
MR	analysis	to	test	for	a	causal	relationship	between	25(OH)D	levels	and	glioma,	using	
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summary	data	from	a	recent	genome-wide	association	study	(GWAS)	meta-analysis	
performed	by	the	Glioma	International	Case-Control	Consortium	(GICC)	9.	 	
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METHODS	
	
Two-sample	MR	was	undertaken	using	GWAS	data.	Ethical	approval	was	not	sought	for	this	
specific	project	because	all	data	came	from	the	summary	statistics	of	previously	published	
GWAS,	and	no	individual-level	data	were	used.		
	
Genetic	variant	instruments	for	25(OH)D	level	
Genetic	variants	used	as	IVs	were	selected	from	the	previously	published	SUNLIGHT	study	7.	
The	SUNLIGHT	Consortium	GWAS	identified	four	genetic	variants	associated	with	lowered	
25(OH)D	levels	in	33,996	individuals	of	European	descent	from	15	cohorts.	These	variants	
were	rs2282679	in	GC	(vitamin	D	binding	carrier	protein),	rs10741657	near	CYP2R1	
(converter	of	vitamin	D	to	the	active	ligand	for	the	vitamin	D	receptor),	rs12785878	near	
DHCR7	(7-dehydrocholesterol	synthesis	from	cholesterol,	a	precursor	to	vitamin	D)	and	
rs6013897	in	CYP24A1	(degrader	of	active	1,25-dihydroxyvitamin	D3	to	inactive	vitamin	D)	
10.	The	roles	of	GC,	CYP2R1,	DHCR7	and	CYP24A1	in	the	vitamin	D	pathway	are	shown	in	
Figure	1.	Association	estimates	(per-allele	log-ORs)	for	SNPs	were	taken	from	previously	
published	studies,	which	used	data	from	the	CaMOS	study,	a	population	based	cohort	study	
of	2,347	Canadians,	genotyped	and	assayed	for	25(OH)D	levels	8,10,11.	None	of	the	SNPs	were	
in	linkage	disequilibrium	(i.e.	r2	≥0.001).	For	each	SNP,	we	recovered	the	chromosome	
position,	risk	allele,	genetic	locus,	F-statistic	and	association	estimates	(Table	1).	Standard	
errors	(SE)	were	calculated	from	F-statistics	calculated	by	previous	studies,	which	derive	
from	the	CaMOS	cohort	11.	The	risk	allele	was	taken	to	be	the	25(OH)D	decreasing	allele.	
Allele	frequencies	for	these	SNPs	were	compared	between	the	25(OH)D	and	glioma	data	
sets	to	ensure	that	the	effect	estimates	were	recorded	with	respect	to	the	same	allele.	This	
study	calculated	the	variants	to	account	for	about	2%	of	the	variation	in	circulating	25(OH)D	
levels,	and	have	a	combined	F-statistic	of	12.57	12.		
	
Glioma	genotyping	data	
Association	data	between	the	four	genetic	variants	and	glioma	were	taken	from	the	most-
recent	meta-analysis	of	GWAS	in	glioma	9,	which	related	>10	million	genetic	variants	(after	
imputation)	to	glioma	(Supplementary	Table	1).	This	meta-analysis	comprised	eight	GWAS	
datasets	of	individuals	of	European	descent:	FRE,	GER,	GICC,	MDA,	GliomaScan	(NIH),	UCSF-
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Mayo,	UCSF	and	UK	(Supplementary	Table	2).	All	diagnoses	were	confirmed	in	accordance	
with	WHO	guidelines.	Full	quality	control	details	are	provided	in	previously	published	work	
9.	Gliomas	are	heterogeneous	and	different	tumour	subtypes,	defined	in	part	by	malignancy	
grade	(for	example,	pilocytic	astrocytoma	World	Health	Organization	(WHO)	grade	I,	diffuse	
‘low-grade’	glioma	WHO	grade	II,	anaplastic	glioma	WHO	grade	III	and	glioblastoma	(GBM)	
WHO	grade	IV)	can	be	distinguished	13.	To	avoid	diagnostic	ambiguity	and	for	simplicity	we	
considered	glioma	subtypes	as	being	either	GBM	or	non-GBM.		
	
Statistical	analyses	
We	examined	the	association	between	circulating	25(OH)D	levels	and	glioma	(including	
subtypes)	using	MR	on	summary	statistics	using	the	inverse	variance	weighted	(IVW)	and	
maximum	likelihood	estimation	(MLE)	methods,	as	described	by	Burgess	et	al.	(2015)	14.	The	
combined	ratio	estimate	(!)	of	all	SNPs	associated	with	25(OH)D	levels	on	glioma	risk	was	
calculated	under	a	fixed-effects	model:	
	
																																																																				! = #$%$&'()#$)&'()*+,- 																																																												(1)	
	.*	is	the	association	between	SNP	k	with	25(OH)D	levels,	/*	is	the	association	between	SNP	
k	and	glioma	risk	with	standard	error	0%.	The	standard	error	of	this	association	is	given	by:	
																																																	
																																																														12 ! = -#$)&'()*+,- 																																																										(2)	
	
We	also	conducted	a	likelihood	based	analysis	using	the	same	genetic	summary	data	15.	For	
this	maximum	likelihood	estimate,	a	bivariate	normal	distribution	for	the	genetic	
associations	was	assumed,	and	the	R	function	optim	was	used	to	estimate	!.	SE(!)	was	
calculated	using	observed	information.	
	
With	the	estimates	from	the	two	analyses	calculated	for	each	of	the	eight	cohorts	in	the	
glioma	data,	we	performed	a	meta-analysis	under	a	fixed-effect	model	to	derive	final	odds	
ratios	(ORs)	and	confidence	intervals	(CIs)	16.			
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To	test	whether	the	variants	chosen	as	instruments	were	valid	under	MR	assumptions,	we	
examined	the	instruments	for	pleiotropy	(multiple	traits	influenced	by	one	gene)	between	
the	exposure	and	disease	risk.	This	would	be	revealed	as	deviation	from	a	linear	relationship	
between	SNPs	and	their	effect	size	for	25(OH)D	levels	and	glioma	risk.	We	performed	MR-
Egger	regression	to	test	the	average	pleiotropic	effect	caused	by	the	variants	combined,	as	
well	as	to	provide	a	third	association	estimate	between	25(OH)D	level	and	glioma	17.	As	per	
Dimitrakopoulou	et	al.	18,	we	further	evaluated	the	presence	of	horizontal	pleiotropy	by	
conducting	stratified	MR	analyses	using	only	the	genetic	variants	influencing	vitamin	D	
synthesis	(rs12785878,	rs10741657)	and	vitamin	D	metabolism	(rs2282679,	rs6013897).	
rs12785878	has	been	associated	with	non-European	status	10	and	we	therefore	also	
undertook	a	sensitivity	analysis	excluding	rs12785878.		
	
For	each	statistical	test,	we	considered	a	global	significance	level	of	P <0.05	as	being	
satisfactory	to	derive	conclusions.	To	assess	the	robustness	of	our	conclusions,	we	imposed	
a	conservative	Bonferroni-corrected	significance	threshold	of	0.017	(i.e.	0.05/3	tumour	
classifications).	
	
The	power	of	a	MR	investigation	depends	greatly	on	the	proportion	of	variance	in	the	risk	
factor	that	is	explained	by	the	IV.	We	therefore	estimated	study	power	to	assess	the	
strength	of	the	results	19.	The	detectable	ORs	at	80%	power	were	1.26	or	0.79	in	the	all	
glioma	analysis,	1.34	or	0.75	in	the	GMB	analysis	and	1.35	or	0.74	in	the	non-GBM	analysis.	
All	power	calculations	were	completed	at	a	significance	level	of	0.05	and	assumed	the	
variants	explained	2%	of	the	total	variance	of	25(OH)D	levels.		
	
Data	availability	
Genotype	data	from	the	GICC	GWAS	are	available	from	the	database	of	Genotypes	and	
Phenotypes	(dbGaP;	accession	phs001319.v1.p1).	Genotype	data	from	the	GliomaScan	
GWAS	can	also	be	accessed	through	dbGaP	(accession	phs000652.v1.p1).	Data	from	the	
other	studies	are	available	upon	request.	
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RESULTS	
	
The	results	of	the	IVW	and	MLE	methods	are	summarised	in	Table	2.	Results	of	the	MR-
Egger	analysis	are	summarised	in	Table	3.	Forest	plots	of	all	results	from	the	IVW	and	MLE	
methods	are	shown	in	Figures	2	and	3.	There	was	no	evidence	to	support	an	association	(i.e.	
P	>0.05)	between	circulating	25(OH)D	levels	and	risk	of	all	glioma	using	either	the	IVW	
(OR=1.21,	95%	CI=0.90-1.62,	P=0.201)	or	MLE	(OR=1.20,	95%	CI=0.98-1.48,	P=0.083)	
methods.	MR-Egger	regression	produced	an	intercept	of	-0.001	(95%	CI=-0.019-0.017,	
P=0.893)	and	therefore	provided	no	evidence	for	pleiotropy	amongst	the	genetic	variants	
chosen	as	IVs	(Supplementary	Figure	1).	Hence	there	was	no	evidence	of	violation	of	MR	
assumptions.			
	
We	explored	the	possibility	that	a	relationship	between	vitamin	D	and	glioma	may	be	
subtype	specific,	considering	GBM	and	non-GBM	separately.	We	imposed	a	stronger	
significance	threshold	of	P=0.017	(i.e.	0.05/3),	to	correct	for	multiple	testing.	The	MLE	
method	identified	an	inverse	relationship	between	25(OH)D	levels	and	risk	of	the	GBM	
subtype,	with	an	OR	of	0.62	(95%	CI=0.43-0.89,	P=0.010).	The	IVW	method	provided	a	
similar,	but	non-significant	effect	size	(OR=0.62,	95%	CI=0.37-1.04,	P=0.070).	No	evidence	
for	an	association	between	25(OH)D	levels	and	the	non-GBM	subtype	was	identified	using	
either	the	IVW	or	MLE	methods.	MR-Egger	regression	provided	intercepts	of	-0.013	(95%	
CI=-0.039-0.012,	P=0.307)	for	GBM	and	-0.005	(95%	CI=-0.035-0.026,	P=0.768)	for	non-GBM,	
again	providing	no	evidence	of	pleiotropy.	
	
Stratified	MR	analyses	using	separate	allelic	scores	for	vitamin	D	synthesis	and	metabolism	
did	not	indicate	the	presence	of	horizontal	pleiotropy	(Supplementary	Tables	3	and	4).	To	
address	the	potential	effects	of	population	stratification,	we	undertook	a	MR	sensitivity	
analysis	excluding	rs12785878,	as	this	SNP	has	been	associated	with	non-European	status	10	
(Supplementary	Table	5).	Excluding	rs12785878,	the	inverse	relationship	between	25(OH)D	
levels	and	risk	of	the	GBM	subtype	identified	by	the	MLE	method	remains	significant	
(OR=0.51,	95%	CI=0.33-0.80,	P=0.003),	thereby	providing	no	evidence	that	this	association	is	
a	result	of	population	stratification.			 	
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DISCUSSION	
		
To	our	knowledge,	this	is	the	first	MR	study	evaluating	the	effect	of	vitamin	D	on	glioma	risk	
undertaken.	Overall	our	results	do	not	provide	evidence	for	an	effect	of	vitamin	D	on	risk	of	
all	forms	of	glioma.	They	do	however	raise	the	possibility	for	a	protective	role	of	vitamin	D	in	
GBM.	While	vitamin	D	and	its	metabolites	have	been	shown	to	induce	death	of	glioblastoma	
cells	20-22,	only	one	epidemiological	study	has	investigated	the	relationship	between	pre-
diagnostic	levels	of	25(OH)D	and	glioma	risk	23.	Researchers	found	that	higher	levels	of	
25(OH)D	were	protective	against	high-grade	glioma	in	men	over	the	age	of	56	(OR=0.59),	
although	the	reverse	trend	was	shown	in	men	under	the	age	of	56,	albeit	at	a	borderline-
significant	level	23.	Excluding	the	possibility	of	post	hoc	data	mining,	such	paradoxical	
findings	would	support	distinct	aetiologies	between	the	GBM	and	non-GBM	subtypes,	as	has	
been	suggested	previously	9.	
	
Vital	to	the	method	of	statistical	analysis	used	herein	is	that	none	of	the	MR	assumptions	
are	violated.	This	requires	that	the	variants	chosen	as	IVs	are	i)	strongly	associated	with	the	
exposure,	ii)	are	not	associated	with	any	confounding	effects	between	exposure	and	
outcome	and	iii)	are	only	associated	with	the	outcome	via	the	exposure.	With	regard	to	this	
study,	the	instruments	chosen	were	associated	with	25(OH)D	levels	at	genome-wide	
significance	levels.	The	MR-Egger	test	provided	no	evidence	of	horizontal	pleiotropy,	which	
we	deemed	sufficient	to	satisfy	the	third	assumption.	Furthermore,	none	of	the	four	SNPs	
were	in	linkage	disequilibrium	(i.e.	r2	≥0.001)	with	any	of	the	variants	identified	by	Melin	et	
al.	9	as	being	in	the	risk	region	for	glioma.	With	regard	to	confounding	factors,	few	risk	
factors	are	known	for	glioma,	so	it	was	not	possible	to	entirely	rule	out	the	possibility	of	
unknown	confounding	factors	causing	statistical	bias.	However	it	should	also	be	noted	that	
all	four	SNPs	lie	either	within	or	near	genetic	loci	whose	function	in	vitamin	D	physiology	is	
well	understood	7,	although	a	lack	of	knowledge	of	possible	confounding	factors	means	it	
was	not	possible	to	entirely	rule	out	the	possibility	of	confounding	by	unknown	factors.	
	
We	acknowledge	that	a	weakness	of	our	study	was	in	the	small	percentage	of	variability	
(around	2%)	in	25(OH)D	levels	explained	by	the	IV.	Such	a	low	value	means	any	
interpretation	of	these	results	as	true	indicators	of	the	effect	of	total	25(OH)D	levels	on	
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glioma	risk	are	limited.	This	is	quantified	by	the	high	ORs	required	for	sufficient	study	
power.	Furthermore	the	study	only	accounts	for	circulating	25(OH)D	levels	and	not	for	the	
action	of	25(OH)D	at	the	cellular	level	11.	The	genetic	variants	used	as	IVs	in	this	MR	analysis	
associate	with	25(OH)D	levels,	rather	than	levels	of	the	biologically	active	1,25-
dihydroxyvitamin	D	(1,25(OH)2D)	and	we	therefore	cannot	explicitly	comment	on	the	
relationship	between	1,25(OH)2D	and	glioma.	The	low	OR	found	in	the	GBM	analysis	should	
be	noted	however,	given	the	fairly	consistent	indications	of	protective	effects	of	25(OH)D	
across	all	three	methods.	As	is	generally	the	case	with	MR,	any	findings	should	be	viewed	as	
a	compliment	to	other	future	epidemiological	studies,	which	test	more	robustly	for	
associations	between	vitamin	D	and	glioma	and	its	subtypes.	
	
In	conclusion	our	MR	analysis	provides	no	evidence	for	an	association	between	vitamin	D	
and	glioma,	though	findings	raise	the	possibility	of	a	potential	association	between	vitamin	
D	and	GBM	warranting	further	investigation.			 	
Takahashi	et	al.	
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Figure	1:	Effect	of	SNPs	chosen	as	IVs	on	the	vitamin	D	pathway.	Genes	that	contain,	or	are	
in	proximity	to,	variants	chosen	as	IVs	are	highlighted	green.	P	values	for	the	association	of	
these	variants	with	25(OH)D	levels	were	1.9	×	10-109	for	GC,	2.1	×	10-27	for	DHCR7,	3.3	×	10-20	
for	CYP2R1,	and	6.0	×	10-10	for	CYP24A1.		
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Figure	2:	Individual	cohort	and	meta-analysis	ORs	calculated	using	the	IVW	method.	(a)	All	
glioma,	(b)	GBM	and	(c)	non-GBM	glioma.	Boxes	are	OR	point	estimates	with	area	
proportional	to	the	weight	of	the	study.	Diamonds	are	overall	summary	estimates,	with	95%	
CIs	given	by	the	width.	Vertical	line	is	null	value	(OR=1.0).	Phet,	P	value	for	heterogeneity;	I2,	
proportion	of	total	variance	due	to	heterogeneity.		
	
	
	
Takahashi	et	al.	
 18 
Figure	3:	Individual	cohort	and	meta-analysis	ORs	calculated	using	the	MLE	method.	(a)	All	
glioma,	(b)	GBM	and	(c)	non-GBM	glioma.	Boxes	are	OR	point	estimates	with	area	
proportional	to	the	weight	of	the	study.	Diamonds	are	overall	summary	estimates,	with	95%	
CIs	given	by	the	width.	Vertical	line	is	null	value	(OR=1.0).	Phet,	P	value	for	heterogeneity;	I2,	
proportion	of	total	variance	due	to	heterogeneity.		
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Table	1:	Genetic	variant	instruments	for	25(OH)D	levels.	EA,	effect	allele;	NEA,	non-effect	
allele;	SE,	standard	error.	Positions	given	using	NCBI	build	37.	EA	taken	to	be	the	25(OH)D	
decreasing	allele.	Effect	taken	to	be	the	per	allele	log	OR	effect	on	25(OH)D.	
	 	
SNP	ID	 Chr	 Locus	 Base	pair	
position	
EA	
glioma	
NEA	
glioma	
EA	
25(OH)D	
NEA	
25(OH)D	
Effect	on	
25(OH)D	
SE	 F-statistic	
rs2282679	 4	 GC	 72608383	 G	 T	 G	 T	 -0.047	 0.013	 13.38	
rs10741657	 11	 Near	CYP2R1	 14914878	 G	 A	 G	 A	 -0.052	 0.012	 18.78	
rs12785878	 11	 Near	DHCR7	 71167449	 T	 G	 G	 T	 -0.056	 0.013	 18.29	
rs6013897	 20	 CYP24A1	 52742479	 A	 T	 A	 T	 -0.027	 0.015	 3.13	
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Table	2:	MR	estimates	between	multi-SNP	risk	scores	of	25(OH)D	levels	and	all	glioma,	
GBM	and	non-GBM	glioma	using	the	IVW	and	MLE	methods.	IVW,	inverse-variance	
weighted;	MLE,	maximum	likelihood	estimation;	SE,	standard	error;	OR,	odds	ratio;	CI,	
confidence	interval;	GBM,	glioblastoma.	
	
.	
	 	
	 IVW	method	 MLE	method	
	 β	 SE(β)	 OR	(95%	CI)	 P	value	 β	 SE(β)	 OR	(95%	CI)	 P	value	
All	glioma	 0.189	 0.148	 1.21	(0.90-1.62)	 0.201	 0.184	 0.106	 1.20	(0.98-1.48)	 0.083	
GBM	 -0.471	 0.261	 0.62	(0.37-1.04)	 0.070	 -0.479	 0.186	 0.62	(0.43-0.89)	 0.010	
Non-GBM	
0.177	 0.281	 1.19	(0.69-2.07)	 0.529	 0.177	 0.199	 1.19	(0.81-1.76)	 0.373	
Takahashi	et	al.	
 21 
Table	3:	MR-Egger	test	results	for	25(OH)D	levels	and	all	glioma,	GBM	and	non-GBM	
glioma.	CI,	confidence	interval;	GBM,	glioblastoma.	
	
	
	
	
	 MR	Egger	slope	 MR	Egger	intercept	
	
Estimate	(95%	CI)	 P	value	 Estimate	(95%	CI)	 P	value	
All	Glioma	 0.072	(-0.121-0.264)	 0.466	 -0.001	(-0.019-0.017)	 0.893	
GBM	 -0.097	(-0.272-0.078)	 0.279	 -0.013	(-0.039-0.012)	 0.307	
Non-GBM	 0.160	(-0.114-0.434)	 0.253	 -0.005	(-0.035-0.026)	 0.768	
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Supplementary	Figure	1:	Egger	plots	showing	association	estimates	and	intercepts	for	IVW	
and	MR-Egger	methods.	(a)	All	glioma,	(b)	GBM	and	(c)	non-GBM	glioma.	Individual	SNP	
results	(x	axis,	association	between	genetic	variant	and	exposure;	y	axis,	association	
between	genetic	variant	and	outcome)	for	MR-Egger	represented	as	dots.	
	
a)	
	
	
	
	
	
	
	
	
	
	
	
	
	
b)	
	
	
	
	
	
	
	
	
	
	
	
	
	
c)		
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Supplementary	Table	1:	Summary	data	taken	from	the	eight	glioma	GWAS	cohorts	for	all	
glioma,	GBM	and	non-GBM	glioma.		
	
	
	
	
	 	 β	(SE)	
	 SNP	ID	 FRE		 GER	 GICC	 MDA	 NIH	 UCSF	
Mayo	
UCSF	 UK	
All	
glioma	
	 	 	 	 	 	 	 	 	
	 rs2282679	 -0.041014	
	(0.061236)	
0.133969	
(0.0722672)	
0.0312392	
(0.0370895)	
-0.0201926	
(0.0583145)	
-0.0334083	
(0.0502593)	
-0.0852	
(0.078)	
0.026953	
(0.0666535)	
-0.083326	
(0.068562)	
	 rs10741657	 -0.043771		
(0.084085)	
-0.0231973	
(0.0104501)	
0.0471905	
(0.0343338)	
0.0227122	
(0.065825)	
0.0827191	
(0.0459571)	
0.0280	
(0.0701)	
0.0155846	
(0.0626787)	
-0.066564	
(0.063921)	
	 rs12785878	 0.010056		
(0.091535)	
0.0670007	
(0.0731303)	
0.103648	
(0.0376908)	
-0.184117	
(0.0741074)	
-0.0277272	
(0.049879)	
-0.0794	
(0.0785)	
-0.077447	
(0.0701056)	
-0.046863	
(0.075283)	
	 rs6013897	 0.069519		
(0.096596)	
-0.135191	
(0.0804649)	
-0.0238725	
(0.0450309)	
-0.0288026	
(0.0643046)	
0.0826986	
(0.0555012)	
-0.11586	
(0.0891)	
0.0171522	
(0.0737805)	
-0.0022402	
(0.078694)	
GBM	 	 	 	 	 	 	 	 	 	
	 rs2282679	 -0.04843		
(0.087789)	
0.194952		
(0.091289)	
0.0428872	
(0.0426909)	
-0.0248584	
(0.0715876)	
0.0531505	
(0.0616334)	
-0.0569	
(0.0927)	
0.052768	
(0.0750633)	
-0.050416	
(0.086665)	
	 rs10741657	 0.04091		
(0.084085)	
-0.0433447	
(0.084627)	
0.0838341	
(0.0398032)	
0.0227122	
(0.065825)	
0.136855	
(0.0563093)	
0.0299	
(0.084)	
-0.0159823	
(0.070422)	
-0.095132	
(0.092758)	
	 rs12785878	 -0.032299		
(0.091535)	
-0.0329982	
(0.091797)	
0.0898337	
(0.0438104)	
-0.184117	
(0.0741074)	
0.0587657	
(0.0615237)	
-0.1273	
(0.0931)	
-0.0522656	
(0.0791768)	
-0.061052	
(0.10893)	
	 rs6013897	 0.20486		
(0.096596)	
-0.220451	
(0.0999851)	
-0.0515566	
(0.0521191)	
-0.00551889	
(0.0788602)	
0.0656293	
(0.0680447)	
-0.1620	
(0.1059)	
0.0109484	
(0.0830175)	
0.078138	
(0.11336)	
Non-
GBM	
	 	 	 	 	 	 	 	 	
	 rs2282679	 -0.037759		
(0.066931)	
0.0659646	
(0.0925085)	
0.0181318	
(0.0467723)	
-0.00983184	
(0.0788454)	
-0.13506	
(0.0799106)	
-0.1066	
(0.0917)	
-0.0557449	
(0.125407)	
-0.050416	
(0.086665)	
	 rs10741657	 -0.080648		
(0.064092)	
-0.00334915	
(0.0856417)	
-0.0131532	
(0.0431055)	
0.000852212	
(0.0718896)	
0.00882211	
(0.0725762)	
0.02888	
(0.083)	
0.137603	
(0.119067)	
-0.045619	
(0.080722)	
	 rs12785878	 0.029065		
(0.070909)	
0.0538005	
(0.0946434)	
0.111379	
(0.0475173)	
-0.136224	
(0.0815494)	
-0.146313	
(0.0785833)	
-0.0601	
(0.0935)	
-0.159781	
(0.132543)	
-0.036517	
(0.095481)	
	 rs6013897	 0.0094937		
(0.075201)	
-0.042059	
(0.101502)	
0.029179	
(0.056441)	
-0.0648037	
(0.0868811)	
0.184169	
(0.0887083)	
-0.0546	
(0.1045)	
0.0411433	
(0.138721)	
-0.063098	
(0.10013)	
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Supplementary	Table	2:	Summary	of	the	eight	glioma	GWAS	cohorts.	
	
Study	series	 Centre		 Sampling	 Cases	 Controls	
FRE	 Groupe	
Hospitalier	
Pitié-
Salpêtrière	
Paris	
Patients	with	glioma	were	selected	through	the	Service	de	Neurologie	Mazarin,	
Groupe	Hospitalier	Pitié-Salpêtrière	Paris.	Individuals	from	the	SU.VI.MAX	
(Supplementation	en	Vitamines	et	MinerauxAntioXydants)	study	were	used	as	
controls.	
1,423	 1,190	
GER	 University	of	
Bonn	
Comprised	of	patients	who	had	undergone	surgery	between	1996	and	2008	for	
glioma	at	the	Department	of	Neurosurgery,	University	of	Bonn	Medical	Center.	
Control	subjects	were	taken	from	three	population	studies:	KORA	(Co-	
operative	Health	Research	in	the	Region	of	Augsburg);	POPGEN	(Population	
Genetic	Cohort)	and	the	Heinz	Nixdorf	Recall	study.	
846	 1,310	
GICC	 GLIOGENE	
Consortium	
Comprised	of	glioma	cases	and	controls	that	were	selected	through	Brigham	and	
Women's	Hospital	(Boston,	Massachusetts),	Case	Western	Reserve	University	
(Cleveland,	Ohio),	Columbia	University	(New	York,	New	York),	the	Danish	
Cancer	Society	Research	Centre	(Copenhagen,	Denmark),	the	Gertner	Institute	
(Tel	Hashomer,	Israel),	Duke	University	(Durham,	North	Carolina),	the	University	
of	Texas	MD	Anderson	Cancer	Center	(Houston,	Texas),	Memorial	Sloan	
Kettering	Cancer	Center	(New	York,	New	York),	the	Mayo	Clinic	(Rochester,	
Minnesota),	NorthShore	HealthSystem	(Chicago,	Illinois),	Umeå	University	
(Umeå,	Sweden),	the	University	of	California,	San	Francisco	(San	Francisco,	
California),	the	University	of	Southern	California	(Los	Angeles,	California),	and	
the	Institute	of	Cancer	Research	(London,	United	Kingdom).	Cases	had	newly	
diagnosed	glioma,	and	controls	had	no	personal	history	of	central	nervous	
system	tumors	at	the	time	of	selection	for	the	studies.	
4,572	 3,286	
MDA	 The	
University	of	
Texas	M.D.	
Anderson	
Cancer	
Center	
Cases	were	ascertained	between	1990	and	2008	through	the	MD	Anderson	
Cancer	Center,	Texas.	Controls	were	taken	from	the	Cancer	Genetic	Markers	of	
Susceptibility	studies.		
1,175	 2,236	
GliomaScan	
(NIH)	
National	
Cancer	
Institute		
Cases	were	newly	diagnosed	glioma	(ICDO-3	codes	9380-9480	or	equivalent),	
and	controls	were	cancer-free.	
1,653	 2,725	
UCSF-Mayo		 Mayo	Clinic	 Comprised	of	Mayo	cases,	UCSF	cases,	and	Mayo	Clinic	Biobank	control	data.		 1,519	 804	
UCSF	
	
University	of	
California,	
San	
Francisco	
Cases	were	adults	with	newly	diagnosed,	histologically	confirmed	glioma.	
Population-based	cases	who	were	diagnosed	between	1991	and	2009	and	who	
were	residing	in	the	six	San	Francisco	Bay	area	counties	were	ascertained	using	
the	Cancer	Prevention	Institute	of	California's	early-case	ascertainment	system.	
Clinic-based	cases	who	were	diagnosed	between	2002	and	2012	were	recruited	
from	the	UCSF	Neuro-oncology	Clinic,	regardless	of	their	place	of	residence.	
From	1991	to	2010,	population-based	controls	from	the	same	residential	area	
as	the	population-based	cases	were	identified	using	random	digit-dialling	and	
were	frequency	matched	to	population-based	cases	for	age,	gender	and	
ethnicity.	Between	2010	and	2012,	all	controls	were	selected	from	the	UCSF	
general	medicine	phlebotomy	clinic.	Clinic-based	controls	were	matched	to	
clinic-based	glioma	cases	for	age,	gender	and	ethnicity.	
677	 3,940	
UK	 INTERPHONE	 Cases	were	ascertained	through	the	INTERPHONE	study.	Controls	were	selected	
from	the	1958	Birth	Cohort.	
631	 2,699	
Total	 		 		 12,496	 18,190	
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Supplementary	Table	3:	MR	estimates	between	multi-SNP	risk	scores	of	25(OH)D	synthesis	
(rs12785878	and	rs10741657)	and	all	glioma,	GBM	and	non-GBM	glioma	using	the	IVW	
and	MLE	methods.		
	
	 IVW	method	 MLE	method	
	 β	 SE(β)	 OR	(95%	CI)	 P	value	 β	 SE(β)	 OR	(95%	CI)	 P	value	
All	glioma	 0.207	 0.161	 1.23	(0.90-1.69)	 0.197	 0.200	 0.117	 1.22	(0.97-1.54)	 0.086	
GBM	 -0.509	 0.315	 0.60	(0.32-1.11)	 0.106	 -0.514	 0.225	 0.60	(0.38-0.93)	 0.023	
Non-GBM	 0.090	 0.338	 1.09	(0.56-2.12)	 0.789	 0.088	 0.242	 1.09	(0.68-1.75)	 0.716	
	
IVW,	inverse-variance	weighted;	MLE,	maximum	likelihood	estimation;	SE,	standard	error;	
OR,	odds	ratio;	CI,	confidence	interval;	GBM,	glioblastoma.	
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Supplementary	Table	4:	MR	estimates	between	multi-SNP	risk	scores	of	25(OH)D	
metabolism	(rs2282679	and	rs6013897)	and	all	glioma,	GBM	and	non-GBM	glioma	using	
the	IVW	and	MLE	methods.		
	
	 IVW	method	 MLE	method	
	 β	 SE(β)	 OR	(95%	CI)	 P	value	 β	 SE(β)	 OR	(95%	CI)	 P	value	
All	glioma	 0.088	 0.382	 1.09	(0.52-2.31)	 0.817	 0.090	 0.271	 1.09	(0.64-1.86)	 0.741	
GBM	 -0.391	 0.464	 0.68	(0.27-1.68)	 0.400	 -0.392	 0.330	 0.68	(0.35-1.29)	 0.234	
Non-GBM	 0.368	 0.503	 1.44	(0.54-3.87)	 0.464	 0.369	 0.357	 1.45	(0.72-2.91)	 0.301	
	
IVW,	inverse-variance	weighted;	MLE,	maximum	likelihood	estimation;	SE,	standard	error;	
OR,	odds	ratio;	CI,	confidence	interval;	GBM,	glioblastoma.	
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Supplementary	Table	5:	MR	estimates	between	multi-SNP	risk	scores	of	25(OH)D	levels	
(excluding	rs12785878,	which	has	been	associated	with	non-European	status)	and	all	
glioma,	GBM	and	non-GBM	glioma	using	the	IVW	and	MLE	methods.		
	
	 IVW	method	 MLE	method	
	 β	 SE(β)	 OR	(95%	CI)	 P	value	 β	 SE(β)	 OR	(95%	CI)	 P	value	
All	glioma	 0.215	 0.161	 1.24	(0.90-1.70)	 0.183	 0.209	 0.115	 1.23	(0.98-1.55)	 0.069	
GBM	 -0.666	 0.319	 0.51	(0.27-0.96)	 0.037	 -0.668	 0.220	 0.51	(0.33-0.80)	 0.003	
Non-GBM	 0.285	 0.344	 1.33	(0.68-2.61)	 0.407	 0.285	 0.244	 1.33	(0.83-2.14)	 0.242	
	
IVW,	inverse-variance	weighted;	MLE,	maximum	likelihood	estimation;	SE,	standard	error;	
OR,	odds	ratio;	CI,	confidence	interval;	GBM,	glioblastoma.	
